Document is current
Any future updates will be listed below
-
Authors
Lurain, Kathryn https://orcid.org/0000-0002-5794-7292
Ramaswami, Ramya
Mangusan, Ralph
Widell, Anaida
Ekwede, Irene
George, Jomy
Ambinder, Richard
Cheever, Martin
Gulley, James L https://orcid.org/0000-0002-6569-2912
Goncalves, Priscila H
Wang, Hao-Wei
Uldrick, Thomas S https://orcid.org/0000-0001-6959-0924
Yarchoan, Robert https://orcid.org/0000-0002-3057-1395
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02595866 at ClinicalTrials.govnct01495598 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
https://doi.org/10.1200/jco.24.00640
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
nct02659930 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
nct00006518 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
nct00092222 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
nct01419561 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
nct02595866 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
nct02595866 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
https://doi.org/10.1200/jco.24.00640
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
nct02595866 at ClinicalTrials.govDocuments that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
https://doi.org/10.1200/jco.24.00640
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Documents that mention this clinical trial
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
https://doi.org/10.1200/jco.24.00640
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
- License Information
